- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
826
Companies which are more than 50% undervalued based on analyst price target.
826 companies
Cantourage Group
Market Cap: €60.4m
Operates as a medical cannabis company in Europe.
HIGH
€4.91
7D
0.2%
1Y
-31.3%
Inotiv
Market Cap: US$66.4m
Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally.
NOTV
US$2.19
7D
7.4%
1Y
-47.5%
Clearside Biomedical
Market Cap: US$66.4m
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
CLSD
US$0.86
7D
-3.2%
1Y
-30.2%
vTv Therapeutics
Market Cap: US$66.3m
A clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.
VTVT
US$21.46
7D
-1.2%
1Y
-17.1%
Pyxis Oncology
Market Cap: US$66.3m
A clinical stage company, engages in the development of therapeutics to treat solid tumors.
PYXS
US$1.15
7D
-3.4%
1Y
-73.2%
Inovio Pharmaceuticals
Market Cap: US$66.0m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.94
7D
4.3%
1Y
-82.9%
IO Biotech
Market Cap: US$65.9m
A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
IOBT
US$1.03
7D
-9.6%
1Y
-27.0%
Unicycive Therapeutics
Market Cap: US$65.8m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$0.57
7D
-12.7%
1Y
-48.1%
Syntara
Market Cap: AU$102.3m
Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia.
SNT
AU$0.063
7D
8.6%
1Y
270.6%
Kalaris Therapeutics
Market Cap: US$65.1m
A clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
KLRS
US$3.48
7D
-35.7%
1Y
n/a
Vistagen Therapeutics
Market Cap: US$64.7m
A biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders.
VTGN
US$2.32
7D
-1.3%
1Y
-48.8%
Nutriband
Market Cap: US$63.6m
Develops a portfolio of transdermal pharmaceutical products.
NTRB
US$5.83
7D
-9.0%
1Y
60.2%
Arovella Therapeutics
Market Cap: AU$99.4m
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.084
7D
-4.5%
1Y
-32.8%
Medicenna Therapeutics
Market Cap: CA$88.4m
An immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.
MDNA
CA$1.13
7D
8.7%
1Y
-54.1%
Curatis Holding
Market Cap: CHF 52.7m
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
CURN
CHF 10.30
7D
3.0%
1Y
28.7%
Transcenta Holding
Market Cap: HK$482.9m
A clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States.
6628
HK$1.19
7D
-4.8%
1Y
-32.8%
Seres Therapeutics
Market Cap: US$61.5m
A clinical-stage company, develops microbiome therapeutics to treat the modulation of the colonic microbiome.
MCRB
US$7.88
7D
-14.6%
1Y
-59.2%
SkinBioTherapeutics
Market Cap: UK£46.6m
A life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally.
SBTX
UK£0.20
7D
-12.1%
1Y
132.6%
Biomea Fusion
Market Cap: US$61.2m
A clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
BMEA
US$1.77
7D
-11.5%
1Y
-84.5%
Citius Oncology
Market Cap: US$61.0m
Focuses on the development of novel targeted oncology therapies.
CTOR
US$0.89
7D
1.5%
1Y
-92.0%
Cabaletta Bio
Market Cap: US$60.4m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$1.29
7D
0.8%
1Y
-88.5%
MAIA Biotechnology
Market Cap: US$60.4m
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
MAIA
US$1.92
7D
0.5%
1Y
-37.0%
Alto Neuroscience
Market Cap: US$60.1m
Operates as a clinical-stage biopharmaceutical company in the United States.
ANRO
US$2.34
7D
-0.4%
1Y
-83.4%
Magle Chemoswed Holding
Market Cap: SEK 586.8m
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden.
MAGLE
SEK 28.60
7D
10.0%
1Y
-11.7%
Acumen Pharmaceuticals
Market Cap: US$59.4m
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
ABOS
US$1.05
7D
1.0%
1Y
-68.8%
Cue Biopharma
Market Cap: US$58.8m
A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.
CUE
US$0.75
7D
-3.5%
1Y
-54.5%
Adverum Biotechnologies
Market Cap: US$58.7m
A clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
ADVM
US$2.71
7D
-24.5%
1Y
-70.4%
Assertio Holdings
Market Cap: US$58.4m
A pharmaceutical company, provides various products to patients in the United States.
ASRT
US$0.62
7D
1.3%
1Y
-41.4%
Immix Biopharma
Market Cap: US$57.9m
A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
IMMX
US$2.09
7D
3.0%
1Y
-3.2%
Repare Therapeutics
Market Cap: US$57.8m
A clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States.
RPTX
US$1.36
7D
-2.9%
1Y
-63.2%
FluoGuide
Market Cap: SEK 555.7m
A clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.
FLUO
SEK 40.80
7D
0.2%
1Y
-19.2%
Applied Therapeutics
Market Cap: US$56.6m
A clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.
APLT
US$0.40
7D
-8.1%
1Y
-91.0%
Metagenomi
Market Cap: US$56.4m
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
MGX
US$1.55
7D
-1.3%
1Y
-76.3%
Skye Bioscience
Market Cap: US$56.1m
A clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
SKYE
US$2.05
7D
3.0%
1Y
-82.0%
Serina Therapeutics
Market Cap: US$55.9m
A biotechnology company, develops drugs to treat neurological diseases and pain.
SER
US$5.64
7D
-0.5%
1Y
-32.1%
ECO Animal Health Group
Market Cap: UK£42.3m
Develops, registers, and markets pharmaceutical products for animals worldwide.
EAH
UK£0.63
7D
-5.3%
1Y
-47.0%